News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avalanche Biotechnologies Boosts IPO As 2 More Biotechs Go Public This Week


7/22/2014 6:41:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Blindness drug developer Avalanche Biotechnologies Inc. boosted its IPO target to $93 million from $86 million, hoping to sell 6.2 million shares at $13 to $15 per share.

In addition, the Menlo Park gene therapy company will receive $10 million from partner and part-owner Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from a private placement of stock, the company said in a Securities and Exchange Commission filing Monday.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES